Real-world analysis of the effect of gefitinib as a first-line therapy in patients with advanced non-small cell lung cancer with mutations.

Background: There have been few studies on the efficacy of tyrosine kinase inhibitors in lung carcinomas. The purpose of this study was to evaluate the effect of gefitinib as a first-line therapy in patients with advanced non-small cell lung cancer (NSCLC) who were positive for epidermal growth factor receptor () mutations.

Methods: This prospective analysis included 120 patients with advanced NSCLC with mutations who were administered gefitinib as the first-line therapy.